结核病患者外周血淋巴细胞亚群检测及临床应用专家共识

2020-10-15 中国医疗保健国际交流促进会 中国防痨杂志.2020.42(10):1009-1016.

结核病(TB)的发生(发展及转归取决于入侵结核分枝杆菌(MTB)的数量、毒力及机体免疫抵抗力。通过流式细胞术分析TB患者外周血淋巴细胞亚群有助于评估患者的免疫状况、免疫功能和免疫平衡。为临床制定免疫干

中文标题:

结核病患者外周血淋巴细胞亚群检测及临床应用专家共识

发布日期:

2020-10-15

简要介绍:

结核病(TB)的发生(发展及转归取决于入侵结核分枝杆菌(MTB)的数量、毒力及机体免疫抵抗力。通过流式细胞术分析TB患者外周血淋巴细胞亚群有助于评估患者的免疫状况、免疫功能和免疫平衡。为临床制定免疫干预措施、观察疗效及判断预后等方面提供实验室检测依据。本专家共识简要地介绍了我国临床常用的淋巴细胞亚群分析项目(包括百分比和绝对计数);提出了AB患者淋巴细胞亚群检测及结果正确判读的建议;简介了淋巴细胞亚群分析在AB患者临床诊疗中的用途,并对未来淋巴细胞亚群检测的发展前景进行了展望。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=结核病患者外周血淋巴细胞亚群检测及临床应用专家共识_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d2e021c002006277, title=结核病患者外周血淋巴细胞亚群检测及临床应用专家共识, enTitle=, guiderFrom=中国防痨杂志.2020.42(10):1009-1016., authorId=0, author=, summary=结核病(TB)的发生(发展及转归取决于入侵结核分枝杆菌(MTB)的数量、毒力及机体免疫抵抗力。通过流式细胞术分析TB患者外周血淋巴细胞亚群有助于评估患者的免疫状况、免疫功能和免疫平衡。为临床制定免疫干, cover=https://img.medsci.cn/2020115/1604591631957_2020535.jpg, journalId=0, articlesId=null, associationId=1199, associationName=中国医疗保健国际交流促进会, associationIntro=中国医疗保健国际交流促进会, copyright=0, guiderPublishedTime=Thu Oct 15 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>结核病(TB)的发生(发展及转归取决于入侵结核分枝杆菌(MTB)的数量、毒力及机体免疫抵抗力。通过流式细胞术分析TB患者外周血淋巴细胞亚群有助于评估患者的免疫状况、免疫功能和免疫平衡。为临床制定免疫干预措施、观察疗效及判断预后等方面提供实验室检测依据。本专家共识简要地介绍了我国临床常用的淋巴细胞亚群分析项目(包括百分比和绝对计数);提出了AB患者淋巴细胞亚群检测及结果正确判读的建议;简介了淋巴细胞亚群分析在AB患者临床诊疗中的用途,并对未来淋巴细胞亚群检测的发展前景进行了展望。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=377, tagName=结核)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=69, categoryName=检验, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=377, guiderKeyword=结核, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3475, appHits=205, showAppHits=0, pcHits=690, showPcHits=3270, likes=0, shares=18, comments=15, approvalStatus=1, publishedTime=Fri Nov 06 00:08:53 CST 2020, publishedTimeString=2020-10-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Nov 05 23:54:00 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 12:41:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=结核病患者外周血淋巴细胞亚群检测及临床应用专家共识_.pdf)])
结核病患者外周血淋巴细胞亚群检测及临床应用专家共识_.pdf
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=976447, encodeId=1adf9e6447e9, content=很好的学习平台, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/176341868a1e467481b3126085dda0a6/4c0bd20baa1b47b5b25fa88cffe06a9c.jpg, createdBy=7dfc5532913, createdName=艾迪迪, createdTime=Thu Jun 24 08:57:04 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917573, encodeId=f46491e57391, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:21:34 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910616, encodeId=b72691061621, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a1f2286122, createdName=zzz-cqmu, createdTime=Thu Dec 24 13:17:16 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901258, encodeId=812e9012586b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:20 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901257, encodeId=62a290125e03, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:16 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2021-06-24 艾迪迪

    很好的学习平台

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=976447, encodeId=1adf9e6447e9, content=很好的学习平台, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/176341868a1e467481b3126085dda0a6/4c0bd20baa1b47b5b25fa88cffe06a9c.jpg, createdBy=7dfc5532913, createdName=艾迪迪, createdTime=Thu Jun 24 08:57:04 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917573, encodeId=f46491e57391, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:21:34 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910616, encodeId=b72691061621, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a1f2286122, createdName=zzz-cqmu, createdTime=Thu Dec 24 13:17:16 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901258, encodeId=812e9012586b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:20 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901257, encodeId=62a290125e03, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:16 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=976447, encodeId=1adf9e6447e9, content=很好的学习平台, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/176341868a1e467481b3126085dda0a6/4c0bd20baa1b47b5b25fa88cffe06a9c.jpg, createdBy=7dfc5532913, createdName=艾迪迪, createdTime=Thu Jun 24 08:57:04 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917573, encodeId=f46491e57391, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:21:34 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910616, encodeId=b72691061621, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a1f2286122, createdName=zzz-cqmu, createdTime=Thu Dec 24 13:17:16 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901258, encodeId=812e9012586b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:20 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901257, encodeId=62a290125e03, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:16 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2020-12-24 zzz-cqmu

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=976447, encodeId=1adf9e6447e9, content=很好的学习平台, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/176341868a1e467481b3126085dda0a6/4c0bd20baa1b47b5b25fa88cffe06a9c.jpg, createdBy=7dfc5532913, createdName=艾迪迪, createdTime=Thu Jun 24 08:57:04 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917573, encodeId=f46491e57391, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:21:34 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910616, encodeId=b72691061621, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a1f2286122, createdName=zzz-cqmu, createdTime=Thu Dec 24 13:17:16 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901258, encodeId=812e9012586b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:20 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901257, encodeId=62a290125e03, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:16 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2020-11-22 随风1991

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=976447, encodeId=1adf9e6447e9, content=很好的学习平台, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/176341868a1e467481b3126085dda0a6/4c0bd20baa1b47b5b25fa88cffe06a9c.jpg, createdBy=7dfc5532913, createdName=艾迪迪, createdTime=Thu Jun 24 08:57:04 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917573, encodeId=f46491e57391, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:21:34 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910616, encodeId=b72691061621, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a1f2286122, createdName=zzz-cqmu, createdTime=Thu Dec 24 13:17:16 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901258, encodeId=812e9012586b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:20 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901257, encodeId=62a290125e03, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/20/44e485222679b3a7b0d5676ca7443126.jpg, createdBy=ef735089224, createdName=随风1991, createdTime=Sun Nov 22 19:58:16 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2020-11-22 随风1991

    不错

    0

拓展阅读

2010 WHO国家指南项目:结核病的治疗(第4版)

世界卫生组织(WHO,The World Health Organization) · 2010-01-01

2010 CDC 使用干扰素释放试验检测结核分枝杆菌感染:美国 2010

美国疾病控制与预防中心(CDC,Centers for Disease Control and Prevention) · 2010-01-01

治疗与控制结核病和糖尿病的合作框架

世界卫生组织(WHO,The World Health Organization) · 2011-01-01

WHO:资源匮乏地区HIV携带者的强化结核病例发现和异烟肼预防性治疗指南

世界卫生组织(WHO,The World Health Organization) · 2011-01-01

2011NICE 肺结核的临床诊治指南及预防措施

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-03-01